Portal de Periódicos da CAPES

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma

2017; Impact Journals LLC; Volume: 8; Issue: 53 Linguagem: Italiano

10.18632/oncotarget.18114

1949-2553

Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Famà, Francesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonio Pinto, Vincenzo Pavone, Filíppo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani,

CNS Lymphoma Diagnosis and Treatment

// Cinzia Pellegrini 1,* , Alessandro Broccoli 1,* , Alessandro Pulsoni 2 , Luigi Rigacci 3 , Caterina Patti 4 , Guido Gini 5 , Donato Mannina 6 , Monica Tani 7 , Chiara Rusconi 8 , Alessandra Romano 9 , Anna Vanazzi 10 , Barbara Botto 11 , Armando Santoro 12 , Stefan Hoaus 13 , Gian Matteo Rigolin 14 , Pellegrino Musto 15 , Patrizio Mazza 16 , Stefano Molica 17 , Paolo Corradini 18 , Angelo Fama 19 , Francesco Gaudio 20 , Michele Merli 21 , Fioravante Ronconi 22 , Giuseppe Gritti 23 , Daniele Vallisa 24 , Patrizia Tosi 25 , Anna Marina Liberati 26 , Antonello Pinto 27 , Vincenzo Pavone 28 , Filippo Gherlinzoni 29 , Maria Paola Bianchi 30 , Stefano Volpetti 31 , Livio Trentin 32 , Maria Cecilia Goldaniga 33 , Maurizio Bonfichi 34 , Amalia De Renzo 35 , Corrado Schiavotto 36 , Michele Spina 37 , Angelo Michele Carella 38 , Vittorio Stefoni 1 , Lisa Argnani 1 and Pier Luigi Zinzani 1 1 Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy 2 Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy 3 Department of Hematology, University and Hospital Careggi, Firenze, Italy 4 Department of Hematology, Azienda Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy 5 Department of Hematology, Ospedali Riuniti di Ancona, Ancona, Italy 6 Hematology Unit, Ospedale Papardo, Messina, Italy 7 Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy 8 Division of Hematology, Niguarda Hospital, Milan, Italy 9 Division of Hematology, AOU, Catania, Italy 10 European Institute of Oncology, Milano, Italy 11 Hematology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy 12 Oncology and Hematology, Humanitas Cancer Center, Rozzano, Italy 13 Institute of Hematology, Catholic University, Rome, Italy 14 Hematology Section, St. Anna University Hospital, Cona, Ferrara, Italy 15 Scientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Pz, Italy 16 Ospedale Moscati, Department of Hematology-Oncology, Taranto, Italy 17 Department of Hematology, Ciaccio-Pugliese Hospital, Catanzaro, Italy 18 Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy 19 Hematology Unit, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy 20 Hematology Unit, Policlinico di Bari, Bari, Italy 21 Hematology, Ospedale di Circolo, Fondazione Macchi, Varese, Italy 22 Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Napoli, Italy 23 Department of Hematology, Hospital Papa Giovanni XXIII, Bergamo, Italy 24 Division of Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy 25 Hematology Unit, Infermi Hospital Rimini, Rimini, Italy 26 Hematology, Ospedale Perugia, Perugia, Italy 27 Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy 28 Division of Hematology, Ospedale G. Panico, Tricase, Lecce, Italy 29 Hematology Unit, Ca' Foncello Hospital, Treviso, Italy 30 Sant'Andrea Hospital, Sapienza University, Rome, Italy 31 Department of Hematology, DISM, Azienda Sanitaria Universitaria Integrata, Udine, Italy 32 Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, Padua, Italy 33 Onco-Hematology Unit, Fondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy 34 Hematology, IRCCS Policlinico San Matteo, Pavia, Italy 35 Hematology, AOU Federico II Napoli, Napoli, Italy 36 Hematology, San Bortolo Hospital, Vicenza, Italy 37 Division of Medical Oncology A, National Cancer Institute, Aviano, Italy 38 Division of Hematology 1, IRCCS A.O.U. San Martino IST, Genova, Italy * These authors have contributed equally to this work Correspondence to: Pier Luigi Zinzani, email: // Keywords : brentuximab vedotin, long-term response, real life, Hodgkin's lymphoma, stem cell transplantation Received : April 04, 2017 Accepted : May 08, 2017 Published : May 23, 2017 Abstract A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.